{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:01:48Z","timestamp":1740106908601,"version":"3.37.3"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:00:00Z","timestamp":1707523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:00:00Z","timestamp":1707523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum RWTH Aachen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Bone marrow biopsy (BMB) is a well-established diagnostic tool for various hematological, oncological, and other medical conditions. However, treatment options for geriatric patients (pts) facing these diseases are often constrained. In this single-center, retrospective analysis we assessed the diagnostic value of BMB in geriatric pts aged\u2009\u2265\u200985 years and examined its impact on therapeutic decisions. We examined 156 BMB procedures in 129 pts, extracting data from the electronic patient records and applying descriptive statistical methods. Nearly half of the primary diagnostic procedures (26; 44.1%) resulted in a modification of the initially suspected diagnosis. Notably, 15 (25.4%) of these procedures, led to changes in both the diagnosis and planned interventional treatment. Among the 15 follow-up procedures (36.6%), disease progression was initially suspected based on symptoms, but BMB results excluded such progression. In lymphoma staging biopsies, only 2 (3.6%) prompted a change in therapeutic intervention. Importantly, no BMB-related complications, such as bleeding, infection or nerve damage, were reported. Median survival after BMB was 16.1 months across all pts, yet it varied based on the diagnosis and comorbidity score. The survival of pts with a change in therapy based on BMB results did not significantly differ from those who did not undergo a therapy change. In conclusion, BMB proved to be generally safe and beneficial in this geriatric cancer patient cohort beyond the age of 85 years. However, the advantages of lymphoma staging in this patient population warrant further consideration.<\/jats:p>","DOI":"10.1007\/s00277-024-05650-x","type":"journal-article","created":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T03:02:22Z","timestamp":1707534142000},"page":"1149-1158","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Bone marrow biopsy in geriatric patients above the age of 85 years: invaluable or unnecessary? A retrospective analysis"],"prefix":"10.1007","volume":"103","author":[{"given":"Kailun David","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edgar","family":"Jost","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Panse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reinhild","family":"Herwartz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"Lindemann-Docter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danny","family":"Jonigk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim","family":"Kricheldorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anja","family":"K\u00f6chel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Sauerbrunn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim H.","family":"Br\u00fcmmendorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steffen","family":"Koschmieder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2855-561X","authenticated-orcid":false,"given":"Susanne","family":"Isfort","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,2,10]]},"reference":[{"key":"5650_CR1","doi-asserted-by":"publisher","unstructured":"United Nations, Department of Economic and Social Affairs (2020) World population ageing 2019. https:\/\/doi.org\/10.18356\/6a8968ef-en","DOI":"10.18356\/6a8968ef-en"},{"issue":"9779","key":"5650_CR2","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1016\/S0140-6736(11)60399-1","volume":"377","author":"MT Seymour","year":"2011","unstructured":"Seymour MT, Thompson LC, Wasan HS, Middleton G, Brewster AE, Shepherd SF, O\u2019Mahony MS, Maughan TS, Parmar M, Langley RE, Investigators F, National Cancer Research Institute Colorectal Cancer Clinical Studies G (2011) Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial. Lancet 377(9779):1749\u20131759. https:\/\/doi.org\/10.1016\/S0140-6736(11)60399-1","journal-title":"Lancet"},{"issue":"5","key":"5650_CR3","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/S1470-2045(11)70069-9","volume":"12","author":"F Peyrade","year":"2011","unstructured":"Peyrade F, Jardin F, Thieblemont C, Thyss A, Emile JF, Castaigne S, Coiffier B, Haioun C, Bologna S, Fitoussi O, Lepeu G, Fruchart C, Bordessoule D, Blanc M, Delarue R, Janvier M, Salles B, Andre M, Fournier M, Gaulard P, Tilly H, Grouped\u2019Etude des Lymphomes de l\u2019Adultei (2011) Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol 12(5):460\u2013468. https:\/\/doi.org\/10.1016\/S1470-2045(11)70069-9","journal-title":"Lancet Oncol"},{"key":"5650_CR4","doi-asserted-by":"publisher","unstructured":"Saiz-Rodriguez M, Labrador J, Cuevas B, Martinez-Cuadron D, Campuzano V, Alcaraz R, Cano I, Sanz MA, Montesinos P (2021) Use of Azacitidine or Decitabine for the Up-Front Setting in Acute Myeloid Leukaemia: A Systematic Review and Meta-Analysis. Cancers (Basel) 13(22). https:\/\/doi.org\/10.3390\/cancers13225677","DOI":"10.3390\/cancers13225677"},{"issue":"6","key":"5650_CR5","doi-asserted-by":"publisher","first-page":"e1405","DOI":"10.1002\/cnr2.1405","volume":"4","author":"Z Saito","year":"2021","unstructured":"Saito Z, Fujita K, Okamura M, Ito T, Yamamoto Y, Kanai O, Hashimoto M, Nakatani K, Sawai S, Mio T (2021) Efficacy and safety of immune checkpoint inhibitors in patients with non-small cell lung cancer aged 80 years or older. Cancer Rep (Hoboken) 4(6):e1405. https:\/\/doi.org\/10.1002\/cnr2.1405","journal-title":"Cancer Rep (Hoboken)"},{"issue":"11","key":"5650_CR6","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1200\/JCO.20.02666","volume":"39","author":"L Oberic","year":"2021","unstructured":"Oberic L, Peyrade F, Puyade M, Bonnet C, Dartigues-Cuilleres P, Fabiani B, Ruminy P, Maisonneuve H, Abraham J, Thieblemont C, Feugier P, Salles G, Bijou F, Pica GM, Damaj G, Haioun C, Casasnovas RO, Farhat H, Le Calloch R, Waultier-Rascalou A, Malak S, Paget J, Gat E, Tilly H, Jardin F (2021) Subcutaneous Rituximab-MiniCHOP Compared With Subcutaneous Rituximab-MiniCHOP Plus Lenalidomide in Diffuse Large B-Cell Lymphoma for Patients Age 80 Years or Older. J Clin Oncol 39(11):1203\u20131213. https:\/\/doi.org\/10.1200\/JCO.20.02666","journal-title":"J Clin Oncol"},{"issue":"12","key":"5650_CR7","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1001\/jamaoncol.2021.4960","volume":"7","author":"CA Nebhan","year":"2021","unstructured":"Nebhan CA, Cortellini A, Ma W, Ganta T, Song H, Ye F, Irlmeier R, Debnath N, Saeed A, Radford M, Alahmadi A, Diamond A, Hoimes C, Ramaiya N, Presley CJ, Owen DH, Abou Alaiwi S, Nassar A, Ricciuti B, Lamberti G, Bersanelli M, Casartelli C, Buti S, Marchetti P, Giusti R, Filetti M, Vanella V, Mallardo D, Macherla S, Sussman TA, Botticelli A, Galetta D, Catino A, Pizzutilo P, Genova C, Dal Bello MG, Kalofonou F, Daniels E, Ascierto PA, Pinato DJ, Choueiri TK, Johnson DB, Marron TU, Wang Y, Naqash AR (2021) Clinical outcomes and toxic effects of single-agent immune checkpoint inhibitors among patients aged 80 years or older with cancer: A multicenter international cohort study. JAMA Oncol 7(12):1856\u20131861. https:\/\/doi.org\/10.1001\/jamaoncol.2021.4960","journal-title":"JAMA Oncol"},{"issue":"1","key":"5650_CR8","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jgo.2019.06.020","volume":"11","author":"F Merli","year":"2020","unstructured":"Merli F, Cavallo F, Salvi F, Tucci A, Musuraca G, Nassi L, Merli M, Tani M, Gini G, Ferrari A, Molinari AL, Liberati AM, Conconi A, Matteucci P, Bari A, Scalone R, Ferrero S, Zanni M, Mammi C, Luminari S (2020) Obinutuzumab and miniCHOP for unfit patients with diffuse large B-cell lymphoma. A phase II study by Fondazione Italiana Linfomi. J Geriatr Oncol 11(1):37\u201340. https:\/\/doi.org\/10.1016\/j.jgo.2019.06.020","journal-title":"J Geriatr Oncol"},{"issue":"4","key":"5650_CR9","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s00262-019-02298-9","volume":"68","author":"V Leroy","year":"2019","unstructured":"Leroy V, Gerard E, Dutriaux C, Prey S, Gey A, Mertens C, Beylot-Barry M, Pham-Ledard A (2019) Adverse events need for hospitalization and systemic immunosuppression in very elderly patients (over 80 years) treated with ipilimumab for metastatic melanoma. Cancer Immunol Immunother 68(4):545\u2013551. https:\/\/doi.org\/10.1007\/s00262-019-02298-9","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"5650_CR10","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.1016\/S2352-3026(16)30171-5","volume":"4","author":"F Peyrade","year":"2017","unstructured":"Peyrade F, Bologna S, Delwail V, Emile JF, Pascal L, Ferme C, Schiano JM, Coiffier B, Corront B, Farhat H, Fruchart C, Ghesquieres H, Macro M, Tilly H, Choufi B, Delarue R, Fitoussi O, Gabarre J, Haioun C, Jardin F (2017) Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group. Lancet Haematol 4(1):e46\u2013e55. https:\/\/doi.org\/10.1016\/S2352-3026(16)30171-5","journal-title":"Lancet Haematol"},{"issue":"6","key":"5650_CR11","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1093\/annonc\/mdr488","volume":"23","author":"TJ Price","year":"2012","unstructured":"Price TJ, Zannino D, Wilson K, Simes RJ, Cassidy J, Van Hazel GA, Robinson BA, Broad A, Ganju V, Ackland SP, Tebbutt NC (2012) Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine. Bevacizumab Mitomycin C Ann Oncol 23(6):1531\u20131536. https:\/\/doi.org\/10.1093\/annonc\/mdr488","journal-title":"Bevacizumab Mitomycin C Ann Oncol"},{"issue":"12","key":"5650_CR12","doi-asserted-by":"publisher","first-page":"e52695","DOI":"10.1371\/journal.pone.0052695","volume":"7","author":"U Krug","year":"2012","unstructured":"Krug U, Koschmieder A, Schwammbach D, Gerss J, Tidow N, Steffen B, Bug G, Brandts CH, Schaich M, Rollig C, Thiede C, Noppeney R, Stelljes M, Buchner T, Koschmieder S, Duhrsen U, Serve H, Ehninger G, Berdel WE, Muller-Tidow C (2012) Feasibility of azacitidine added to standard chemotherapy in older patients with acute myeloid leukemia\u2013a randomised SAL pilot study. PLoS One 7(12):e52695. https:\/\/doi.org\/10.1371\/journal.pone.0052695","journal-title":"PLoS One"},{"issue":"7","key":"5650_CR13","doi-asserted-by":"publisher","first-page":"152447","DOI":"10.1016\/j.prp.2019.152447","volume":"215","author":"Q Le Clef","year":"2019","unstructured":"Le Clef Q, Menter T, Tzankov A (2019) Our approach to bone marrow biopsies in cytopenia. Pathol Res Pract 215(7):152447. https:\/\/doi.org\/10.1016\/j.prp.2019.152447","journal-title":"Pathol Res Pract"},{"issue":"9","key":"5650_CR14","first-page":"1293","volume":"91","author":"BJ Bain","year":"2006","unstructured":"Bain BJ (2006) Morbidity associated with bone marrow aspiration and trephine biopsy - a review of UK data for 2004. Haematologica 91(9):1293\u20131294","journal-title":"Haematologica"},{"issue":"4","key":"5650_CR15","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1136\/jcp.2004.022178","volume":"58","author":"BJ Bain","year":"2005","unstructured":"Bain BJ (2005) Bone marrow biopsy morbidity: review of 2003. J Clin Pathol 58(4):406\u2013408. https:\/\/doi.org\/10.1136\/jcp.2004.022178","journal-title":"J Clin Pathol"},{"issue":"5","key":"5650_CR16","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1111\/j.1365-2257.2004.00630.x","volume":"26","author":"BJ Bain","year":"2004","unstructured":"Bain BJ (2004) Bone marrow biopsy morbidity and mortality: 2002 data. Clin Lab Haematol 26(5):315\u2013318. https:\/\/doi.org\/10.1111\/j.1365-2257.2004.00630.x","journal-title":"Clin Lab Haematol"},{"issue":"6","key":"5650_CR17","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1046\/j.1365-2141.2003.04329.x","volume":"121","author":"BJ Bain","year":"2003","unstructured":"Bain BJ (2003) Bone marrow biopsy morbidity and mortality. Br J Haematol 121(6):949\u2013951. https:\/\/doi.org\/10.1046\/j.1365-2141.2003.04329.x","journal-title":"Br J Haematol"},{"issue":"4","key":"5650_CR18","first-page":"548","volume":"78","author":"NP McGoldrick","year":"2012","unstructured":"McGoldrick NP, Green C, Connolly P (2012) Gluteal compartment syndrome following bone marrow biopsy: a case report. Acta Orthop Belg 78(4):548\u2013551","journal-title":"Acta Orthop Belg"},{"issue":"3","key":"5650_CR19","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.jocn.2005.03.027","volume":"13","author":"RM Lowenthal","year":"2006","unstructured":"Lowenthal RM, Taylor BV, Jones R, Beasley A (2006) Severe persistent sciatic pain and weakness due to a gluteal artery pseudoaneurysm as a complication of bone marrow biopsy. J Clin Neurosci 13(3):384\u2013385. https:\/\/doi.org\/10.1016\/j.jocn.2005.03.027","journal-title":"J Clin Neurosci"},{"issue":"1","key":"5650_CR20","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/bjh.15630","volume":"184","author":"M Khakwani","year":"2019","unstructured":"Khakwani M, Srinath S, Pratt G, Moss P (2019) A rare complication of bone marrow aspiration and trephine biopsy: Staphylococcus aureus osteomyelitis and septicaemia. Br J Haematol 184(1):7. https:\/\/doi.org\/10.1111\/bjh.15630","journal-title":"Br J Haematol"},{"issue":"1","key":"5650_CR21","doi-asserted-by":"publisher","first-page":"823","DOI":"10.4081\/cp.2016.823","volume":"6","author":"A Morotti","year":"2016","unstructured":"Morotti A, Barozzino MC, Guerrasio A (2016) rare bone marrow biopsy complication: A challenging case of Sacroiliitis and Staphilococcus Aureus Sepsis. Clin Pract 6(1):823. https:\/\/doi.org\/10.4081\/cp.2016.823","journal-title":"Clin Pract"},{"key":"5650_CR22","first-page":"D952","volume":"161","author":"D Houtman","year":"2017","unstructured":"Houtman D, Barten DG, Laurent-de Gast AN (2017) A woman with inguinal pain after a bone marrow biopsy. Ned Tijdschr Geneeskd 161:D952","journal-title":"Ned Tijdschr Geneeskd"},{"issue":"4","key":"5650_CR23","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1159\/000358173","volume":"23","author":"I Berber","year":"2014","unstructured":"Berber I, Erkurt MA, Kuku I, Kaya E, Kutlu R, Koroglu M, Yigit A, Unlu S (2014) An unexpected complication of bone marrow aspiration and trephine biopsy: arteriovenous fistula. Med Princ Pract 23(4):380\u2013383. https:\/\/doi.org\/10.1159\/000358173","journal-title":"Med Princ Pract"},{"issue":"3","key":"5650_CR24","doi-asserted-by":"publisher","first-page":"e25","DOI":"10.4081\/hr.2011.e25","volume":"3","author":"M Sarigianni","year":"2011","unstructured":"Sarigianni M, Vlachaki E, Chissan S, Klonizakis F, Vetsiou E, Anastasiadou KI, Ioannidou-Papagiannaki E, Klonizakis I (2011) Haematoma caused by bone marrow aspiration and trephine biopsy. Hematol Rep 3(3):e25. https:\/\/doi.org\/10.4081\/hr.2011.e25","journal-title":"Hematol Rep"},{"key":"5650_CR25","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13256-016-0827-5","volume":"10","author":"Y Al Zahrani","year":"2016","unstructured":"Al Zahrani Y, Peck D (2016) Median sacral artery injury following a bone marrow biopsy successfully treated with selective trans-arterial embolization: a case report. J Med Case Rep 10:42. https:\/\/doi.org\/10.1186\/s13256-016-0827-5","journal-title":"J Med Case Rep"},{"key":"5650_CR26","doi-asserted-by":"publisher","first-page":"489","DOI":"10.12659\/AJCR.889274","volume":"14","author":"WF Wan Jamaludin","year":"2013","unstructured":"Wan Jamaludin WF, Mohamed Mukari SA, Abdul Wahid SF (2013) Retroperitoneal hemorrhage associated with bone marrow trephine biopsy. Am J Case Rep 14:489\u2013493. https:\/\/doi.org\/10.12659\/AJCR.889274","journal-title":"Am J Case Rep"},{"issue":"10","key":"5650_CR27","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1093\/gerona\/59.10.m1068","volume":"59","author":"R Mistry","year":"2004","unstructured":"Mistry R, Gokhman I, Bastani R, Gould R, Jimenez E, Maxwell A, McDermott C, Rosansky J, Van Stone W, Jarvik L, Group UC (2004) Measuring medical burden using CIRS in older veterans enrolled in UPBEAT, a psychogeriatric treatment program: a pilot study. J Gerontol A Biol Sci Med Sci 59(10):1068\u20131075. https:\/\/doi.org\/10.1093\/gerona\/59.10.m1068","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"5","key":"5650_CR28","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1111\/j.1532-5415.1968.tb02103.x","volume":"16","author":"BS Linn","year":"1968","unstructured":"Linn BS, Linn MW, Gurel L (1968) Cumulative illness rating scale. J Am Geriatr Soc 16(5):622\u2013626. https:\/\/doi.org\/10.1111\/j.1532-5415.1968.tb02103.x","journal-title":"J Am Geriatr Soc"},{"issue":"12","key":"5650_CR29","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","volume":"370","author":"V Goede","year":"2014","unstructured":"Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, Chagorova T, de la Serna J, Dilhuydy MS, Illmer T, Opat S, Owen CJ, Samoylova O, Kreuzer KA, Stilgenbauer S, Dohner H, Langerak AW, Ritgen M, Kneba M, Asikanius E, Humphrey K, Wenger M, Hallek M (2014) Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 370(12):1101\u20131110. https:\/\/doi.org\/10.1056\/NEJMoa1313984","journal-title":"N Engl J Med"},{"issue":"10","key":"5650_CR30","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1111\/j.1532-5415.2008.01935.x","volume":"56","author":"F Salvi","year":"2008","unstructured":"Salvi F, Miller MD, Grilli A, Giorgi R, Towers AL, Morichi V, Spazzafumo L, Mancinelli L, Espinosa E, Rappelli A, Dessi-Fulgheri P (2008) A manual of guidelines to score the modified cumulative illness rating scale and its validation in acute hospitalized elderly patients. J Am Geriatr Soc 56(10):1926\u20131931. https:\/\/doi.org\/10.1111\/j.1532-5415.2008.01935.x","journal-title":"J Am Geriatr Soc"},{"issue":"15","key":"5650_CR31","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.1002\/cncr.31554","volume":"124","author":"MJ Gordon","year":"2018","unstructured":"Gordon MJ, Churnetski M, Alqahtani H, Rivera X, Kittai A, Amrock SM, James S, Hoff S, Manda S, Spurgeon SE, Choi M, Cohen JB, Persky D, Danilov AV (2018) Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib. Cancer 124(15):3192\u20133200. https:\/\/doi.org\/10.1002\/cncr.31554","journal-title":"Cancer"},{"key":"5650_CR32","unstructured":"Federal Statistical Office of Germany, Robert-Koch Institute: Gesundheitsberichtserstattung des Bundes. 2002 and 2022. https:\/\/www.gbe-bund.de\/gbe\/!pkg_olap_tables.prc_set_page?p_uid=gast&p_aid=69135500&p_sprache=D&p_help=2&p_indnr=524&p_ansnr=27031407&p_version=6&D.001=1000001&D.003=42"},{"key":"5650_CR33","unstructured":"Federal Statistical Office of Germany, Robert-Koch Institute: Gesundheitsberichtserstattung des Bundes. 2002 and 2022. https:\/\/www.gbe-bund.de\/gbe\/!pkg_olap_tables.prc_set_page?p_uid=gast&p_aid=69135500&p_sprache=D&p_help=2&p_indnr=524&p_ansnr=27031407&p_version=7&D.001=1000001&D.003=43"},{"issue":"1","key":"5650_CR34","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/ajh.26050","volume":"96","author":"A Tefferi","year":"2021","unstructured":"Tefferi A (2021) Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management. Am J Hematol 96(1):145\u2013162. https:\/\/doi.org\/10.1002\/ajh.26050","journal-title":"Am J Hematol"},{"issue":"2","key":"5650_CR35","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/bjh.13853","volume":"172","author":"SB Killick","year":"2016","unstructured":"Killick SB, Bown N, Cavenagh J, Dokal I, Foukaneli T, Hill A, Hillmen P, Ireland R, Kulasekararaj A, Mufti G, Snowden JA, Samarasinghe S, Wood A, Marsh JC, British Society for Standards in H (2016) Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol 172(2):187\u2013207. https:\/\/doi.org\/10.1111\/bjh.13853","journal-title":"Br J Haematol"},{"issue":"20","key":"5650_CR36","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391\u20132405. https:\/\/doi.org\/10.1182\/blood-2016-03-643544","journal-title":"Blood"},{"issue":"12","key":"5650_CR37","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","volume":"120","author":"PL Greenberg","year":"2012","unstructured":"Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Krieger O, Luebbert M, Maciejewski J, Magalhaes SM, Miyazaki Y, Pfeilstocker M, Sekeres M, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D (2012) Revised international prognostic scoring system for myelodysplastic syndromes. Blood 120(12):2454\u20132465. https:\/\/doi.org\/10.1182\/blood-2012-03-420489","journal-title":"Blood"},{"issue":"10","key":"5650_CR38","doi-asserted-by":"publisher","first-page":"7197","DOI":"10.1007\/s00432-023-04669-3","volume":"149","author":"A Schmidt","year":"2023","unstructured":"Schmidt A, Bernhardt C, Burkle D, Fries S, Hannig CV, Jentsch-Ullrich K, Josting A, Kreher S, Reiser M, Steinmetz HT, Tesch H, Terner S, Schulte A, Crodel CC, Palandri F, Heidel FH (2023) Diagnosis and treatment of MPN in real life: exploratory and retrospective chart review including 960 MPN patients diagnosed with ET or MF in Germany. J Cancer Res Clin Oncol 149(10):7197\u20137206. https:\/\/doi.org\/10.1007\/s00432-023-04669-3","journal-title":"J Cancer Res Clin Oncol"},{"issue":"5","key":"5650_CR39","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1309\/AJCPXPPIF21LJJCZ","volume":"130","author":"EM Manion","year":"2008","unstructured":"Manion EM, Rosenthal NS (2008) Bone marrow biopsies in patients 85 years or older. Am J Clin Pathol 130(5):832\u2013835. https:\/\/doi.org\/10.1309\/AJCPXPPIF21LJJCZ","journal-title":"Am J Clin Pathol"},{"key":"5650_CR40","doi-asserted-by":"publisher","unstructured":"Han EJ, O JH, Yoon H, Ha S, Yoo IR, Min JW, Choi JI, Choi BO, Park G, Lee HH, Jeon YW, Min GJ, Cho SG (2022) Comparison of FDG PET\/CT and Bone Marrow Biopsy Results in Patients with Diffuse Large B Cell Lymphoma with Subgroup Analysis of PET Radiomics. Diagnostics (Basel) 12(1). https:\/\/doi.org\/10.3390\/diagnostics12010222","DOI":"10.3390\/diagnostics12010222"},{"issue":"10","key":"5650_CR41","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.clml.2017.06.010","volume":"17","author":"P Vishnu","year":"2017","unstructured":"Vishnu P, Wingerson A, Lee M, Mandelson MT, Aboulafia DM (2017) Utility of bone marrow biopsy and aspirate for staging of diffuse large b cell lymphoma in the era of positron emission tomography with 2-Deoxy-2-[Fluorine-18]fluoro-deoxyglucose integrated with computed tomography. Clin Lymphoma Myeloma Leuk 17(10):631\u2013636. https:\/\/doi.org\/10.1016\/j.clml.2017.06.010","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"5650_CR42","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa2115304","volume":"386","author":"H Tilly","year":"2022","unstructured":"Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trneny M, Sharman JP, Herbaux C, Burke JM, Matasar M, Rai S, Izutsu K, Mehta-Shah N, Oberic L, Chauchet A, Jurczak W, Song Y, Greil R, Mykhalska L, Bergua-Burgues JM, Cheung MC, Pinto A, Shin HJ, Hapgood G, Munhoz E, Abrisqueta P, Gau JP, Hirata J, Jiang Y, Yan M, Lee C, Flowers CR, Salles G (2022) Polatuzumab vedotin in previously untreated diffuse large B-Cell Lymphoma. N Engl J Med 386(4):351\u2013363. https:\/\/doi.org\/10.1056\/NEJMoa2115304","journal-title":"N Engl J Med"},{"issue":"8","key":"5650_CR43","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1093\/annonc\/mdq671","volume":"22","author":"E Weidmann","year":"2011","unstructured":"Weidmann E, Neumann A, Fauth F, Atmaca A, Al-Batran SE, Pauligk C, Jager E (2011) Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas. Ann Oncol 22(8):1839\u20131844. https:\/\/doi.org\/10.1093\/annonc\/mdq671","journal-title":"Ann Oncol"},{"issue":"5","key":"5650_CR44","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.3109\/10428194.2013.821201","volume":"55","author":"R Hamilton","year":"2014","unstructured":"Hamilton R, Andrews I, McKay P, Leach M (2014) Loss of utility of bone marrow biopsy as a staging evaluation for Hodgkin lymphoma in the positron emission tomography-computed tomography era: a West of Scotland study. Leuk Lymphoma 55(5):1049\u20131052. https:\/\/doi.org\/10.3109\/10428194.2013.821201","journal-title":"Leuk Lymphoma"},{"issue":"36","key":"5650_CR45","doi-asserted-by":"publisher","first-page":"4508","DOI":"10.1200\/JCO.2012.42.4036","volume":"30","author":"TC El-Galaly","year":"2012","unstructured":"El-Galaly TC, d\u2019Amore F, Mylam KJ, de Nully BP, Bogsted M, Bukh A, Specht L, Loft A, Iyer V, Hjorthaug K, Nielsen AL, Christiansen I, Madsen C, Johnsen HE, Hutchings M (2012) Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography\/computed tomography-staged treatment-naive patients with Hodgkin lymphoma. J Clin Oncol 30(36):4508\u20134514. https:\/\/doi.org\/10.1200\/JCO.2012.42.4036","journal-title":"J Clin Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05650-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05650-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05650-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T10:08:28Z","timestamp":1710410908000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05650-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,10]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["5650"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05650-x","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2024,2,10]]},"assertion":[{"value":"17 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study has been approved by local Ethics Committee (Internal file number EK 309\/22).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"KDZ, EJ, JP, RH, KL-D, DJ, KK, AK, NS and SK report no competing interests to declare that are relevant to the content of this article. THB served as consultant\/speaker for Gilead, Janssen, Merck, Novartis, Pfizer, and received research support from Novartis and Pfizer. SI reports advisory board honoraria from GSK, Pfizer, Incyte, and Novartis, honoraria from Novartis, BMS, Pfizer, Incyte, AOP Orphan; and other financial support (e.g. travel support) from Alexion, Novartis, Pfizer, Mundipharma, Roche, Hexal and AOP Orphan.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}